Launched: I-MAK’s Special Edition Roadmap on Tenofovir Alafenamide Fumarate (TAF)
A critical analysis of TAF, as part of a Roadmap series, aims to help the international community assess the best...
Gilead’s patent application on sofosbuvir rejected in Brazil
Rejected! That was the decision issued by Brazil’s National Institute of Industrial Property (INPI) over one of Gilead’s patent applications...
Ukraine eyes patent law reform after civil society push on medicines access
Ukrainian lawmakers are poised to approve sweeping patent reform legislation, driven in large part by a push by patients’ groups...
ADVOCATES PUBLISH COMMENTARY ON EXPANDING TREATMENT ACCESS FOR VIRAL HEPATITIS C
On 2 April 2018, an in-depth commentary on practical actions that can help increase access to HCV direct-action antivirals (DAAs)...
Patent on Hep C drug rejected in Ukraine: Price of sofosbuvir will significantly reduce
The Ministry of Economic Development and Trade of Ukraine (MEDT) refused to grant the pharmaceutical company Gilead a patent for...
Fundación GEP opposes patent on HIV drug Tenofovir (TAF) in Argentina
Pharmaceutical patent would block access to HIV medicines. Our partner is opposing the patent application in a bid to make...
Fixing the broken patent system: From Marrakech and back again
Marrakech was home to the signing of the TRIPS Agreement in 1995, an agreement that has been exploited by pharmaceutical...
Storify: Pathways to Access #GSIPA2M
[View the story “Pathways to Access! #GSIPA2M (15-17 Jan 2018)” on Storify] SaveSave
GSIPA2M: The Summit Highlights
Catch up on the activity from our inaugural Global Summit on Intellectual Property and Access to Medicines (15-17 January 2018)....
IP and access to medicines: welcome speech
Our inaugural Global Summit on Intellectual Property and Access to Medicines has started today. Read Solange Baptiste’s welcoming speech below,...